Anebulo's Cannabinoid Intoxication Reversal Agent Effective in Netherlands Study
The Phase II study, conducted in the Netherlands, evaluated the single-dose ANEB-001 in treating healthy participants affected by THC. Anebulo plans to file an IND with the FDA by the end of 2022.